A Cross-Sectional Study on Prescription Patterns of Short-Acting β
exacerbations
inhaled corticosteroids
over-prescription
practice patterns
prescriptions
Journal
Journal of asthma and allergy
ISSN: 1178-6965
Titre abrégé: J Asthma Allergy
Pays: New Zealand
ID NLM: 101543450
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
03
2022
accepted:
20
08
2022
entrez:
2
9
2022
pubmed:
3
9
2022
medline:
3
9
2022
Statut:
epublish
Résumé
Overuse of short-acting β This observational, cross-sectional cohort study of SABINA III included patients (aged ≥12 years) with asthma recruited from seven sites in Colombia. Demographics, disease characteristics (including investigator-defined asthma severity guided by the 2017 Global Initiative for Asthma report), and asthma treatments prescribed (including SABAs and inhaled corticosteroids [ICS]) in the 12 months preceding the study were recorded using electronic case report forms during a single study visit. Of 250 patients analyzed, 50.4%, 33.2%, and 16.4% were enrolled by pulmonologists, general medicine practitioners, and allergists, respectively. Most patients were female (74.0%) and had moderate-to-severe asthma (67.6%). Asthma was partly controlled or uncontrolled in 57.6% of patients, with 15.6% experiencing ≥1 severe exacerbation 12 months before the study visit. In total, 4.0% of patients were prescribed SABA monotherapy and 55.6%, SABA in addition to maintenance therapy. Overall, 39.2% of patients were prescribed ≥3 SABA canisters in the 12 months before the study visit; 25.2% were prescribed ≥10 canisters. Additionally, 17.6% of patients purchased SABAs over the counter, of whom 43.2% purchased ≥3 canisters. Maintenance medication in the form of ICS or ICS/long-acting β Our findings suggest that prescription/purchase of ≥3 SABA canisters were common in Colombia, highlighting a public health concern. There is a need to improve asthma care by aligning clinical practices with the latest evidence-based treatment recommendations to improve asthma management across Colombia.
Identifiants
pubmed: 36051434
doi: 10.2147/JAA.S365009
pii: 365009
pmc: PMC9427209
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1167-1178Informations de copyright
© 2022 Pedrozo-Pupo et al.
Déclaration de conflit d'intérêts
Dr Andrea Carolina Caballero Pinilla reports personal fees from SANOFI, personal fees from GLAXO SMITHKLINE, personal fees from NOVARTIS, outside the submitted work. LBV is an employee of AstraZeneca and is the R&I Manager for the Andean Cluster. MB was an employee of AstraZeneca at the time this study was conducted. All other authors have no conflicts of interest to disclose.
Références
Ann Allergy Asthma Immunol. 2012 Dec;109(6):403-7
pubmed: 23176877
Eur Respir J. 2022 May 5;59(5):
pubmed: 34561293
Rev Panam Salud Publica. 2005 Mar;17(3):191-7
pubmed: 15826399
J Asthma. 2021 Aug;58(8):991-994
pubmed: 32482150
Eur Respir J. 2020 Feb 12;55(2):
pubmed: 31806716
World Allergy Organ J. 2020 Apr 01;13(4):100113
pubmed: 32256940
BMJ Open. 2019 Jan 29;9(1):e022506
pubmed: 30696669
Patient Prefer Adherence. 2020 Mar 10;14:541-551
pubmed: 32210541
BMC Pulm Med. 2019 Jul 9;19(1):123
pubmed: 31288777
East Mediterr Health J. 2010 Feb;16(2):171-5
pubmed: 20799570
Respir Med. 2017 Oct;131:135-140
pubmed: 28947020
J Bras Pneumol. 2009 Jul;35(7):635-44
pubmed: 19669001
BMC Pulm Med. 2012 Jul 13;12:17
pubmed: 22551171
Chest. 1999 Oct;116(4 Suppl 1):145S-154S
pubmed: 10532476
MEDICC Rev. 2017 Jul;19(2-3):65
pubmed: 34352980
Thorax. 2015 Sep;70(9):898-905
pubmed: 26103996
Value Health Reg Issues. 2014 Dec;5:25-28
pubmed: 29702783
World Allergy Organ J. 2018 Nov 12;11(1):26
pubmed: 30459927
J Asthma. 2020 Feb;57(2):113-122
pubmed: 30915868
Nat Rev Dis Primers. 2015 Sep 10;1:15025
pubmed: 27189668
World Allergy Organ J. 2013 Nov 04;6(1):19
pubmed: 24180521
J Bras Pneumol. 2020 Mar 02;46(1):e20190307
pubmed: 32130345